- Home
- BIIB vs DTE Comparison
BIIB vs DTE Comparison
Compare BIIB & DTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- DTE
- Stock Information
- Founded
- BIIB 1978
- DTE 1903
- Country
- BIIB United States
- DTE United States
- Employees
- BIIB N/A
- DTE N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- DTE Electric Utilities: Central
- Sector
- BIIB Health Care
- DTE Utilities
- Exchange
- BIIB Nasdaq
- DTE Nasdaq
- Market Cap
- BIIB 25.1B
- DTE 26.1B
- IPO Year
- BIIB 1991
- DTE N/A
- Fundamental
- Price
- BIIB $149.02
- DTE $120.76
- Analyst Decision
- BIIB Buy
- DTE Buy
- Analyst Count
- BIIB 26
- DTE 16
- Target Price
- BIIB $248.00
- DTE $131.38
- AVG Volume (30 Days)
- BIIB 1.6M
- DTE 1.4M
- Earning Date
- BIIB 02-11-2025
- DTE 02-06-2025
- Dividend Yield
- BIIB N/A
- DTE 3.61%
- EPS Growth
- BIIB 10.05
- DTE 21.85
- EPS
- BIIB 11.06
- DTE 7.38
- Revenue
- BIIB $9,607,500,000.00
- DTE $12,415,000,000.00
- Revenue This Year
- BIIB N/A
- DTE $2.48
- Revenue Next Year
- BIIB N/A
- DTE $2.50
- P/E Ratio
- BIIB $13.47
- DTE $16.37
- Revenue Growth
- BIIB N/A
- DTE N/A
- 52 Week Low
- BIIB $145.07
- DTE $102.17
- 52 Week High
- BIIB $268.30
- DTE $131.67
- Technical
- Relative Strength Index (RSI)
- BIIB 32.44
- DTE 46.75
- Support Level
- BIIB $145.07
- DTE $116.65
- Resistance Level
- BIIB $149.92
- DTE $120.49
- Average True Range (ATR)
- BIIB 3.81
- DTE 2.02
- MACD
- BIIB 0.05
- DTE -0.10
- Stochastic Oscillator
- BIIB 22.51
- DTE 63.04
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About DTE DTE Energy Company
DTE Energy owns two regulated utilities in Michigan that contribute 90% of earnings. DTE Electric serves approximately 2.3 million customers in southeastern Michigan, including Detroit. DTE Gas serves 1.3 million customers throughout the state. In addition, DTE has nonutility businesses and investments including energy marketing and trading, renewable natural gas facilities, and on-site industrial energy projects.